NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Tuesday,Benzinga reports. The firm currently has a $31.00 price objective on the stock.

A number of other equities analysts have also commented on the company. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Trading Down 4.8 %

Shares of NRXP opened at $2.99 on Tuesday. The stock’s 50-day moving average price is $2.39 and its two-hundred day moving average price is $1.93. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The company has a market capitalization of $36.15 million, a PE ratio of -1.40 and a beta of 1.08.

Insiders Place Their Bets

In related news, Chairman Jonathan C. Javitt acquired 40,000 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were bought at an average price of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. This trade represents a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.